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The role of serum components in enhancing virus neutralizing (VN) activity of influenza virus A/PR/8/34 hemagglutinin (HA)-specific MAbs
in vitro was investigated. The degree of enhancement depended on the MAb's fine specificity and heavy chain isotype and on type of serum.
Greatest enhancement (>100-fold) was seen with sera from immunodeficient mice that lacked serum immunoglobulin. At least two serum
components were involved: C1q and a heat-resistant factor. C1q was mandatory for enhancement, and other components of the complement
system were not required. C1q appeared to operate by improving MAb-mediated inhibition of virus attachment to host cells and was most
effective with MAbs that inhibited virus attachment poorly on their own. The heat-resistant factor enhanced VN activity only in the presence of
C1q and appeared to operate by enhancing VN activity at a post-attachment stage.
© 2006 Elsevier Inc. All rights reserved.Keywords: Virus neutralization; Influenza A virus; C1q; Complement; Ab-mediated protectionIntroduction
Antibodies (Abs) play important roles in protection against
and recovery from influenza virus infection (reviewed in
Gerhard, 2001). They may contribute to the control of the in-
fection by reaction with (i) infectious virus particles and thereby
impair their infectivity and/or (ii) infected host cells and thereby
limit the yield of virus progeny. Abs may mediate protective
activities autonomously or in conjunction with other host com-
ponents such as complement, Fc-receptor (FcR)-expressing cells
and lectins.
In a previous study, we compared four influenza virus
HA-specific MAbs of G2a isotype for VN activity in vitro and
prophylactic activity in a passive transfer system in vivo
(Mozdzanowska et al., 1997). Although VN activity in vitro
and Ab-mediated prophylaxis in vivo appear to measure similar
Ab-mediated activities, we found that the four MAbs exhibited
surprisingly large discrepancies in these activities. For instance,
one MAb directed to the antigenic region Cb, which is located⁎ Corresponding author. Wistar Institute, 3603 Spruce Street, Philadelphia,
PA, 19104-4268, USA. Fax: +1 215 898 3868.
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doi:10.1016/j.virol.2006.05.008membrane-proximal of the sialic acid (SA) binding site of HA
(Fig. 1) (Caton et al., 1982), exhibited VN activity in vitro at
2.5 μg/ml (Ab concentration at which 50% of MDCK cell
cultures are protected from infection by 100 TCID50 of virus)
and prophylactic activity in vivo at 8 μg/ml (serum Ab con-
centration at which 50% of SCID mice are protected from
intranasal infection by 200 TCID50) (Mozdzanowska et al.,
1997, and unpublished observations). By contrast, another MAb
of the same isotype but directed to the antigenic region Sb of HA,
which is located membrane-distal of the SA binding site (Fig. 1)
(Caton et al., 1982), displayed 2500-fold greater VN activity in
vitro (0.001 μg/ml) but only eight-fold greater prophylactic
activity (1 μg/ml serum). Thus, in relation to their VN activity in
vitro, these MAbs differed by∼300-fold in prophylactic activity
in vivo. This suggested that components/conditions in vivo
differentially affected their prophylactic activity, e.g., by inhi-
biting Sb-specific or enhancing Cb-specific MAbs. The latter
appeared more likely in view of the finding that performance of
the VN assay in vitro in the presence of 1.6% non-inactivated
serum resulted in preferential enhancement of the VN activity of
Cb-specific MAbs (Mozdzanowska et al., 1997). The general
relation between Ab fine specificity and differential enhance-
ment of their hemagglutination inhibition (HI) activity by serum
Fig. 1. Location of antigenic regions on HA relative to the sialic acid (SA)
binding site. The 3D structure of the HA timer of H3 subtype HA (Wilson et al.,
1981) is shown in side view, with the left monomer in lighter and the right
monomer in darker blue. The viral membrane is to be located at the bottom edge
of the figure. The location of amino acid replacements in escape mutants used
for identification of antigenic regions Sa (magenta), Sb (blue), Ca (green) and
Cb (yellow) of PR8 are superimposed onto the H3 structure. The designation of
the corresponding sites in the H3 model (Wiley et al., 1981) is indicated in
brackets. The brown circle shows the approximate location of the SA binding
site on one of the monomers.
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HA-specific MAbs (Feng et al., 2002).
Here, we describe further studies on the enhancement of Ab-
mediated VN activity by serum components. We found that at
least two serum components were involved: C1q, the binding
moiety of the first complement component, and a still un-
defined heat-resistant factor, whose enhancing activity was
dependent on C1q. A high concentration of this factor in sera of
mice that lacked serum immunoglobulin appeared to account
for their elevated VN enhancing activity. C1q appeared to
enhance VN activity at the pre-attachment stage and was
effective mainly with MAbs that inhibited virus attachment
poorly on their own. By contrast, the heat-resistant factorFig. 2. Measurement of VNE. An example of a typical VN assay is shown. (A) Dilu
37 °C in medium without (open symbols) or with 0.5% non-inactivated SCID serum
then transferred to washed MDCK cell microcultures and incubated for 1 h at 37 °C
trypsin) and tested after 3–4 days of incubation for evidence of virus replication. (B)
TCID50/ml) in the absence or presence of non-inactivated SCID serum. Replicate sam
cell microcultures and incubated for 1 h at 37 °C before replacement of the inoculum w
for evidence of virus replication and the MAb concentration required for protecting
percentage of cumulative non-infected cultures at each MAb dilution is shown. The d
measures VNE and is indicated by the two-sided arrow. (C) VNE was determined as
mean and SEM of 3–5 independent determinations.appeared to enhance VN activity at a post-attachment stage and
was similarly effective with MAbs of high or low autonomous
VN activity.
Results
Measurement of virus neutralization enhancement (VNE)
VNEwas assessed in theMDCK cell assay bymeasuring Ab-
mediated VN activity in the absence and presence of 0.5% non-
inactivated naive mouse serum (NMS). Briefly, dilutions of
MAb were incubated in parallel for 60 min at 37 °C with 100
TCID50 of PR8 virus in medium with or without 0.5% non-
inactivated NMS. Replicate samples were then transferred to
MDCK cell microcultures and incubated for another 60 min at
37 °C to allow initiation of infection by residual infectious virus.
The inocula were then replaced by serum-free medium and the
cultures tested for productive infection after 3–4 days of
incubation. In the absence of MAb, 0.5% NMS had usually no
measurable effect on virus infectivity as shown by titration of the
virus inoculum in medium with or without NMS (Fig. 2A).
Nevertheless, this control was performed in each assay to iden-
tify and exclude occasional serum batches that displayed sig-
nificant VN activity on their own. By contrast, when HA-
specific MAbs were tested in the presence and absence of 0.5%
NMS, their VN activity (defined as Ab concentration at which
50% of microcultures were protected from infection) was often
greatly enhanced in the presence of serum. The difference in VN
activity in the presence versus absence of NMS was defined as
VNE and is 92 in the example shown in Fig. 2B. VNE decreased
with decreasing concentration of NMS and became insignificant
below 0.05% of NMS (Fig. 2C).
SCID sera mediate stronger VNE than BALB/c sera
We noticed that SCID NMS mediated 10–20 times stronger
VNE than BALB/c NMS against the HA(Cb)-specific MAb
H35-C12. To determine whether this was a peculiarity of H35-tions of the virus challenge dose (∼2000 TCID50/ml) were incubated for 1 h at
(both without MAb). Replicate samples (6 × 50 μl) of each virus dilution were
. The inoculum was replaced by culture medium (ISC-CM, 0.1% BSA, 1 μg/ml
Dilutions of MAb H35-C12 were incubated for 1 h at 37 °C with PR8 (∼2000
ples (12 × 50 μl) of each Ab-virus mixture were transferred to washed MDCK
ith culture medium as above. After 3–4 days of incubation, cultures were tested
50% of the cultures determined by the method of Reed and Munch (1938). The
ifference in MAb-mediated VN activity in the absence versus presence of NMS
above with SCID serum at the indicated concentrations. Each symbol shows the
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G2a isotype and specificity for the antigenic region Cb of HA.
All displayed substantially stronger VN activity in the presence
of 0.5% SCID (148 ± 124, mean, SD) than BALB/c NMS
(18 ± 9) (Fig. 3). The same was true for MAbs directed to the
antigenic region Sb of HA, although in this case VNE was
roughly 10 times smaller than seen with HA(Cb)-specificMAbs.
These findings indicated that HA(Cb)-specific MAbs, which in
general display low autonomous VN activity in the absence of
serum, are more susceptible for serum-mediated enhancement
than HA(Sb)-specific MAbs, which typically display high
autonomous VN activity. Furthermore, they suggested that
VNE may comprise two distinct and possibly superimposed
activities: one mediated by BALB/c NMS and effective in
a specificity-dependent fashion (HA(Cb)>HA(Sb)) and the
other mediated by SCID NMS and effective in a specificity-
independent fashion.
VNE is dependent on the Ab's Fc region and heavy chain
isotype
The role of the Fc region in VNE was investigated with intact
IgG and Fab fragment from the HA(Sb)-specific MAb H36-4.
As reported previously (Mozdzanowska et al., 2003), IgG and
Fab from this MAb exhibited similar VN activity in the absence
of serum, but only intact IgG and not Fab were enhanced in the
presence of NMS (Fig. 4A). The role of CH isotype in VNE was
investigated with five HA(Cb)-specific MAbs. As found
previously in the serum-mediated enhancement of Ab-mediated
HI activity (Feng et al., 2002), MAbs of G3, G2b and G2a
isotypes showed higher VNE than those of G1 and M isotypesFig. 3. The level of VNE mediated by BALB/c and SCID sera differs and
depends on the specificity of the MAb. HA(Cb)- and HA(Sb)-specific MAbs of
G2a isotype were tested for VN activity without (open columns) and with 0.5%
BALB/c serum (shaded columns) or SCID serum (filled columns). Columns
show arithmetic means and SD of two independent measurements except in the
case of H35-C12 (4 measurements) and H36-4 (3 measurements).(Fig. 4B). Taken together, these findings indicated that serum
mediated VNE through interaction with the Ab's Fc portion and
not by increasing, for instance, the sensitivity of the virus to
become neutralized by MAb or by decreasing the susceptibility
of MDCK cells for becoming infected.
VNE requires C1q but not C3
We have shown previously that C1q, the binding moiety of
the first complement component, was responsible for enhance-
ment of Ab-mediated HI activity by non-inactivated BALB/c-
and B6 sera (Feng et al., 2002). To investigate the role of C1q in
VNE, SCID NMS was mixed with an equal volume of goat-
anti-human (hu)C1q antiserum or PBS, incubated for 1 h at
room temperature and then tested for VNE at a final mouse
serum concentration of 0.5%. This treatment reduced VNE
activity of SCID NMS by ∼99% as did heat inactivation (Fig.
5A). The dependence of VNE on C1q was confirmed by the
observation that sera from C1q−/− mice (B6 background) lacked
VNE. By contrast, sera from C3−/− mice (B6) exhibited similar
VNE as sera from intact B6 mice, indicating that activation of
C3, the central complement component, was not required (Fig.
5B). Furthermore, activation of C4 and C2 was not required
either as purified human C1q (huC1q) at 0.5 μg/ml, which
corresponds roughly to the concentration of C1q in 0.5% NMS
(Kerr et al., 1986), exhibited similar VNE as 0.5% B6 NMS,
both when diluted in serum-free (BSA-containing) medium or
in non-inactivated serum from C1q−/− mice (Fig. 5B). In-
creasing C1q concentration to 2.5 μg/ml resulted in increased
VNE.
These findings were consistent with the notion that C1q was
the sole serum component involved in VNE. If so, a difference
in C1q concentration may explain the difference in VNE
activity mediated by BALB/c and SCID NMS. However, since
the latter was not the case (Fig. 5C), the results suggested that,
apart from C1q, an additional serum component contributed to
VNE.
A heat-resistant factor contributes to VNE
The difference in VNE mediated by BALB/c and SCID
NMS could be due to an inhibitory factor in BALB/c NMS or an
enhancing factor in SCID NMS.
The former possibility was tested with mixtures of non-
inactivated sera from JHD mice, which exhibit high VNE
similar to SCID (see below) and heat-inactivated (no VNE) or
non-inactivated BALB/c NMS (low VNE). As shown in Fig.
6A, neither heat-inactivated nor non-inactivated BALB/c sera
reduced the high VNE of JHD sera, indicating that sera from
BALB/c mice did not contain a VNE inhibitory factor.
Next, we performed the reciprocal experiment and tested
heat-inactivated SCID sera for ability to enhance VNE when
mixed with non-inactivated BALB/c sera. Because of the sub-
stantial range in VNE exhibited by the non-inactivated BALB/c
sera used in these experiments, samples that were tested in the
same experiment are indicated by connecting lines (Fig. 6B), i.e.,
non-inactivated and inactivated SCID serum, non-inactivated
Fig. 4. VNE depends on the Ab's Fc region. (A) Intact IgG and Fab fragment of the HA(Sb)-specific MAb H36-4 were tested for VN activity in the absence and
presence of 0.5% BALB/c and SCID serum. Columns show mean VN activity (±SEM) of three independent assays. (B) HA(Cb)-specific MAbs with the indicated CH
isotypes were tested for VNE by 0.5% SCID serum. Each column shows mean VNE of two independent assays.
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non-inactivated BALB/c sera. The results showed that heat-
inactivated SCID sera, while lacking VNE activity on their own,
consistently enhanced VNE when added to non-inactivated
BALB/c sera. The smallest enhancement was seen with the
SCID serum that exhibited the smallest VNE prior to heat
inactivation (Fig. 5B, triangles pointing down). A relatively
small enhancement was seen also with a BALB/c serum that
mediated high VNE by itself (Fig. 5C, assays marked by circles),
possibly because this serum contained a sufficient concentration
of the enhancing factor.
Taken together, these observations indicated that at least two
serum factors contributed to VNE, the heat-labile C1q and a
heat-resistant factor. The latter appeared to be present at higher
concentration in SCID than BALB/c sera.
VNE by sera of mice with various types of immunodeficiencies
In view of the marked difference in VNE mediated by sera of
immunocompetent (BALB/c, B6) and immunodeficient (SCID)
mice, we screened sera from mice with other types of
immunodeficiencies for VNE. The HA(Cb)-specific MAb
H35-C12 was used in all assays. Fig. 7 shows VNE mediated
mostly by sera from individual mice. BALB/c sera exhibited a
wide range of VNE (1 to 284) with a geometric mean titerFig. 5. C1q is required for VNE. (A) SCID sera were mixed with PBS or goat-anti-h
against MAb H35-C12. A sample of PBS-treated SCID serum was heated for 30 min
serum- or heat-treated serum was expressed as percent of VNE seen with untreated
assays. (B) Purified huC1q at 0.5 μg/ml and 2.5 μg/ml in medium containing 0.1% B
0.5 μg/ml in 0.5% serum from C1q−/− B6 mice and 0.5% serum from C3−/− B6 mice w
of at least three independent assays. (C) Sera from individual mice of the indicated s
arithmetic means of individual sera within each group.(GMT) of 10. Note that the serumwith the very high VNE of 284
was tested in two independent assays, one indicating a VNE of
174 and the other of 395. B6 sera exhibited a slightly but not
significantly lower VNE (GMT = 5). As mentioned previously,
SCID seramediated significantly higher VNE (GMT= 103) than
BALB/c sera (non-parametric t test, P < 0.001). Similarly, sera
from JHD mice on BALB/c background, which contain T cells
but lack mature B cells and serum Ig, exhibited high VNE
(GMT = 155) as did B cell deficient μMT mice on B6 back-
ground (data not shown). Sera from a membrane IgM-transgenic
and JH-deleted mouse strain (Chan et al., 1999), which contains
T- and transgenic IgM-expressing B cells but essentially no
secreted Ig except for some IgA (data not shown), also gave high
VNE (GMT = 224). In the case of nude mice of BALB/c
background, we found that many sera exhibited significant VN
activity on their own at a concentration of 0.5% and were
excluded from the graph. However, five sera with low VN
activity exhibited low VNE (GMT = 15). As indicated by the
deficiencies of the various mouse strains, high VNE was seen in
mouse strains that lacked serum Ig.
Discussion
The study showed that the VN activity of HA-specific
MAbs was significantly enhanced when the assay wasuC1q antiserum, incubated for 1 h at room temperature and then tested for VNE
at 56 °C before being assayed for VNE. In each experiment, VNE seen with anti-
(PBS) SCID serum. Columns show mean %VNE (+SEM) of four independent
SA but no other serum components, 0.5% serum from C1q−/− B6 mice, huC1q at
ere tested for VNE against MAb H35-C12. Columns show mean VNE (±SEM)
trains were tested by ELISA for relative C1q concentration. Cross bars indicate
Fig. 6. Assessment of sera for additional factors that contribute to VNE.
(A) Non-inactivated sera from JHD mice were tested at 0.5% on their own or in
combination with 0.5% heat-inactivated (ΔT) or non-inactivated BALB/c sera
for VNE against MAb H35-C12. VNE by 0.5% of the heat-inactivated and non-
inactivated BALB/c sera on their own is also shown. Columns give the mean
VNE (±SEM) of 4–6 independent assays. (B) Non-inactivated and heat-
inactivated (ΔT) sera (0.5%) from SCID and BALB/c mice were tested alone
and in combination for VNE against MAb H35-C12. Symbols connected by a
line mark the samples tested in the same assay. Sera from distinct individual
mice were used in all but the assays marked by circles, in which case the same
serum was tested twice in independent assays.
Fig. 7. VNE mediated by sera from different strains of mice. Sera from
individual mice of the indicated strains were tested for VNE against the HA
(Cb)-specific MAb H35-C12 (G2a). In general, dots show the result from a
single assay performed with serum from and individual donor mouse. Presence
(+) or absence (−) of T cells, B cells and serum Ig is indicated below each
strain.
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from SCID mice. The degree of enhancement depended on
the MAb's fine specificity – HA(Cb)-specific MAbs being
more strongly enhanced than HA(Sb)-specific MAbs – and its
heavy chain isotype – MAbs of G2a, G2b and G3 isotypes
were more strongly enhanced than G1 and M. We provided
evidence that at least two serum components were involved:
C1q, the heat-labile binding moiety of the first component of
complement, and a still unidentified heat-resistant factor,
which appeared to be present at higher concentration in sera of
mice that lacked circulating Ig than in sera of Ig competent
mice(Fig. 7).
Enhancement of Ab-mediated VN activity in vitro by serum
components has been reported previously for a variety of viruses
(reviewed in Hirsch, 1982; Parren and Burton, 2001) including
influenza A (Beebe et al., 1983). The common denominator of
previous reports was the requirement for antiviral antibodies,
which usually originated from the early immune response and
presumably were of low avidity (Daniels et al., 1969; Hirsch,
1982; Linscott and Levinson, 1969) or displayed a unique
specificity and exhibited poor VN activity on their own (Britt et
al., 1988; Furebring et al., 2002). In addition, there was a
common requirement for components of the classic complement
pathway. The various systems differed, however, with regard to
the extent of complement activation that was required for
enhancement of VN activity, which ranged from activation of
early components (C1, C4) (Daniels et al., 1969) to activation of
the entire complement cascade including the formation of the
membrane attack complex (Vasantha et al., 1988). Overall, the
present observations fit well into this general picture in that (1)
the Cb-specific MAbs, which showed the greatest susceptibility
for enhancement, are a dominant component of the primary Ab
response (Kavaler et al., 1990, 1991) and display low VN
activity on their own (Fig. 3) and (2) a component of the classic
complement pathway is involved. The findings described here
are unique, however, in that only C1q was required for
enhancement. Although we have evidence for deposition ofC3 during incubation of virus-Ab complexes in vitro in the
presence of 0.5% NMS (unpublished observation), the latter
was not required for VNE as indicated by similar levels of
VNE mediated by sera from intact and C3−/− mice (Fig. 5). We
conclude that C4 and C2 deposition were not required either
because purified huC1q, when used at a concentration corres-
ponding to its anticipated concentration in 0.5% NMS,
provided the expected level of VNE seen with intact serum
(Fig. 5B).
The findings of this study are unique also in that a second
serum component was shown to contribute to VNE. The nature
of this component is presently unknown. Its sole known
property is its heat stability, which allowed us to differentiate it
from heat-labile C1q and reveal its presence in SCID mouse
sera. We assume that a high concentration of this factor is
responsible for the high VNE mediated by sera from SCID mice
and probably also for high VNE mediated by exceptional sera
from BALB/c mice (Figs. 6 and 7). Interestingly, the factor
appeared to be present at increased concentration in sera from
mice that lacked serum Ig. This excludes it from being an Ab
with specificity for C1q or Ab Fc region, such as rheumatoid
factor. Because this heat-resistant factor mediated no VNE on its
own, as shown by complete abrogation of VNE upon treatment
of sera with anti-C1q Ab (Fig. 5A) or heat inactivation (Fig.
6B), but substantially improved VNE when admixed to non-
inactivated BALB/c serum, it most likely operated through
interaction with C1q.
Infection of a cell by influenza virus progresses through
several steps, starting with the attachment of virus to cellular
ligands, receptor-mediated endocytosis, maturation and
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acid-mediated fusion between viral and endosomal membranes,
which ultimately results in the release of viral RNA–protein
complexes into the cell's cytoplasm and their transport into the
cell's nucleus for transcription (Chu and Whittaker, 2004;
Lakadamyali et al., 2003; Sieczkarski and Whittaker, 2003).
Both attachment and fusion are mediated by HA, the former by
interaction of the HA's sialic acid (SA) binding site with cellular
ligands and the latter by a complex acid-induced conformational
rearrangement of HA trimers (Skehel and Wiley, 2000). Most
HA-specific Abs, including the HA(Sb)-specific MAb H36-4,
which bind to regions that are membrane distal of the SA
binding site or recognize epitopes that encompass part of the SA
binding site, are thought to prevent infection by inhibition of
virus attachment (Knossow et al., 2002). However, there is
evidence for a minority of Abs that block infection at a post-
attachment stage (for review, see Dimmock, 1993; Edwards
and Dimmock, 2001; Imai et al., 1998). The HA(Cb)-specific
MAb H35-C12 is an example of the latter type of Abs.
Binding of this MAb to the Cb region, which is membrane-
proximal of the SA binding site (Fig. 1), did not significantly
inhibit virus attachment to chicken erythrocytes (Table 1, low
HI activity) or to MDCK cells, even at Ab saturation
(Mozdzanowska et al., 1997; observations to be published).
Yet, H35-C12 exhibited a low level of VN activity (Table 1),
which apparently resulted from interference with a post-
attachment step of virus entry.
How did C1q and the heat-resistant factor enhance Ab-
mediated VN? In the case of C1q, which can interact with a wide
range of ligands, it is clear that VNE resulted from its interaction
with the Ab's Fc region rather than with virus or MDCK cells, as
it had no effect at all on the VN activity of a Fab fragment (Fig.
4A). A likely explanation is that attachment of the large C1q
(460 kDa) to HA-bound MAb resulted in increased steric
hindrance of the attachment of virus to cellular ligands (Fig. 8).
Accordingly, in the case of the HA(Cb)-specific MAb H35-C12,
which was ineffective by itself in preventing virus attachment to
chicken erythrocytes, deposition of C1q to virus-bound MAb
resulted in a 131-fold enhancement of HI activity and a con-
comitant, though smaller, increase of VN activity (Table 1). TheTable 1
Enhancement of HI and VN activity of MAbs H35-C12 and H36-4 by BALB/c-
NMS and SCID-NMS
Assay
conditions
GMT of MAb activity in μg/ml, (n), [enhancement]
H35-C12 (Cb) H36-4 (Sb)
HI VN HI VN
No seruma 51 (2) 3.1 (50) 0.17 (18) 0.0059 (9)
BALB/c
NMSb
0.39 (9) [131] 0.42 (25) [7] 0.090 (8) [2] 0.0042 (9) [1]
SCID
NMSb
0.36 (8) [142] 0.035 (26)[89] 0.041 (5) [4] 0.0008 (2) [7]
a No serummeans PBSN in the case of HI assay and ISC-CM containing 0.1%
BSA in the case of VN assay.
b Non-inactivated sera were used at a final concentration of 0.5%. Entries are
geometric mean titers (number of independent determinations) and [enhancement
compared to no serum value].10 times smaller enhancement seen with the HA(Cb)-specific
MAb of IgG1 isotype (Fig. 4B) can be explained by C1q's low
affinity for this isotype and the low enhancement of HA(Cb)-
specific IgM, to which C1q binds well, by the large size of IgM
(950 kDa), which probably made already full use of inhibition by
steric hindrance. In the case of the HA(Sb)-specific MAb H36-4,
which strongly inhibited by itself attachment of virus to chicken
erythrocytes (Table 1, high HI activity), increased bulk by
deposition of C1q would not be expected to result in much
further enhancement of Ab-mediated HI and VN activities, as
was found (Table 1). Thus, C1q appeared to mediate VNE by
improving Ab-mediated inhibition of virus attachment to cel-
lular ligands and, not surprisingly, was particularly effective in
the case of MAbs that bound to HA but inhibited virus attach-
ment poorly on their own (Fig. 8). Analogous relations between
Ab fine specificity and enhancement of its functional activity by
C1q may operate in other virus systems.
The heat-resistant serum factor appeared to operate differ-
ently. First, in contrast to C1q, it affected only VN activity but
not HI activity (Table 1, no increase in HI titer in presence of
SCID compared to BALB/c NMS), and second, it had a similar
effect on both HA(Cb)- and HA(Sb)-specific MAbs (Table 1,
∼10-fold enhancement of VN activity of both MAbs by SCID
compared to BALB/c NMS). These findings suggest that, unlike
C1q, this factor enhanced VN at a post-attachment stage. Further
studies are needed to identify the nature of this factor and the
precise stage and mechanism of action. Also, our arguments are
based on the assumption that HI provides an adequate assess-
ment of virus attachment to MDCK cells, and that BALB/c and
SCIDNMS are adequate surrogates for C1q and the combination
of C1q and heat-resistant factor, respectively. These assumptions
need to be validated.
The preferential enhancement of the VN activity of HA(Cb)-
specific Abs by C1q in vitro prompted us to test whether C1q
contributed to the unexpectedly high prophylactic activity of
these MAbs in vivo. To this end, we measured the prophylactic
activity of passive HA(Cb)-specific MAb H35-C12 in C1q-
competent and -deficient mice. We found (data not shown)
that H35-C12 did not exhibit higher prophylactic activity in
C1q-competent compared to C1q-deficient mice. Thus, C1q-
mediated enhancement of this MAb's VN activity did not
underlie its unexpectedly high prophylactic activity in vivo.
However, as virus-Ab complexes formed in vitro in the
presence of serum exhibited significantly lower infectivity
when inoculated into mice than virus-Ab complexes formed in
the absence of serum (unpublished observation), the respiratory
tract epithelium was susceptible to the C1q-mediated enhance-
ment phenomenon. Therefore, the most likely reason for not
seeing a C1q-dependent enhancement of prophylactic activity
in vivo may be an insufficient C1q activity in lining fluid of the
non-inflamed respiratory tract, for which there is experimental
support (Giclas et al., 1987; Watford et al., 2001). It is con-
ceivable, however, that C1q-mediated enhancement becomes
operative at later stages of infection when an increasing inflam-
matory response results in increasing exudation of serum
components into the respiratory tract. This possibility remains
to be tested.
Fig. 8. Schematic presentation of the different effects C1q has on attachment of Ab-opsonized virus to cellular ligands, depending on the Ab's fine specificity. (A) The
binding of Sb-specific MAb to an HA epitope that is membrane distal of the SA binding site – and possibly may include a portion of the SA binding site – effectively
inhibits per se the interaction of the SA binding site with cellular ligands (terminal SA on carbohydrate moieties). Deposition of C1q to virus-bound Ab only minimally
improves this inhibition. (B) Binding of Cb-specific MAb to an epitope that does not include a portion of the SA binding site and is membrane-proximal fails to inhibit
the interaction of SA binding site with cellular ligands. (C) However, upon deposition of C1q (460 kDa) to virus-bound Ab, the SA/ligand interaction becomes strongly
inhibited by steric interference.
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complexity in virus neutralization in vitro and even greater
complexity in vivo.
Materials and methods
Virus
Influenza Avirus PR8 [A/PuertoRico/8/34(H1N1), Mt. Sinai
strain] was propagated in the allantoic cavity of embryonated
hen's eggs. The titer of infectious virus was determined by
limiting dilution in microcultures of Madin Darby canine kidney
(MDCK) cells as described (Liang et al., 1994) and 50% tissue
culture infectious dose (TCID50) determined by the method of
Reed and Munch (1938). Infectious stocks typically contained
∼109 TCID50/ml. Aliquots were stored frozen (−70 °C). Purified
virus was prepared from a large batch of allantoic fluid by
differential centrifugation and banding in a sucrose gradient and
was quantified by HA titration (Scherle et al., 1992) and deter-
mination of protein concentration by the BioRad protein assay
(biorad.com).
Media and solutions
ISC-CM consists of Iscove's Dulbecco's medium (Life
Technologies, Gaithersburg, MD) supplemented with 0.05 mM
2-mercaptoethanol, 0.005 mg/ml of transferrin (Sigma, St.
Louis, MO), 2 mM glutamine (JRH Biosciences, Leneza KS),
and 0.05 mg/ml of gentamicin (Mediatech, Herdon, VA). ISC-
CM was further supplemented with fetal bovine serum (FCS)
(HyClone Laboratories, Logan, UH), bovine serum albumine
(BSA) (Sigma), trypsin (Whittaker Bioproducts Inc.), naïve
mouse serum (NMS), human C1q (huC1q) (Calbiochem, La
Jolla, CA) at specified concentrations. PBSN is phosphatebuffered saline containing 3 mM NaN3. PBS(Ca,Mg) is PBS
containing 0.9 mM CaCl2 and 0.5 mM MgCl2.
Mice and sera
BALB/c mice were obtained from HSD (harlan.com),
C57BL/6 (B6) and mice with disrupted transmembrane μ exon
(μMT) on the B6 background from Jackson Laboratories (jax.
org). Nude mice on BALB/c background were purchased from
NxGen, Biosciences. C.B-17 mice, homozygous for the severe
combined immunodeficiency mutation (SCID), were purchased
from the Breeding Facility of the Wistar Institute. Two breeding
pairs of mice with disrupted C3 gene on the B6 background
(C3−/−) (Wessels et al., 1995) were provided by Mike Carroll
(CBR, Harvard Medical School, Boston). Breeding pairs of
C1q−/− mice on B6 background (Botto et al., 1998) were
provided by Valery Fadok (National Jewish Research Center,
Denver) with permission from M. Walport and M. Botto.
Breeding pairs of JH-deficient mice (JHD) (Chen et al., 1993) on
BALB/c background were provided by Mark Shlomchik (Yale).
All mice were housed in micro-isolator cages and were
maintained under pathogen free conditions. Sera from 10 JHD
mice that contained a heavy chain V region transgene with a
disrupted μ secretion exon and polyadenylation site (Chan et al.,
1999) were kindly provided by Mark Shlomchik (Yale). Normal
human serum was obtained from a healthy volunteer and C1q-
depleted human serum purchased from Calbiochem.
Antibodies and reagents
The main MAb used here, H35-C12-6.2 (H35-C12), was
generated from a BALB/cmouse undergoing a primary response
to PR8 (Kavaler et al., 1990) and is specific for the Cb site of the
HA of PR8. It is of G2a/κ isotype. Its sequence (Kavaler et al.,
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determined. H36-4-5.2 (G2a/κ, anti-Sb) and Fab derived from it
have been described elsewhere (Mozdzanowska et al., 2003).
MAbs were purified from hybridoma culture supernatant by
adsorption to and elution from protein A agarose (Piercenet.
com). MAb in the eluate was concentrated by ultrafiltration
through Amicon Ultra filter devices with 50,000 MWexclusion
(Millipore). Protein concentration was determined by UV light
absorption (A280) and chemical protein assay as described
(Mozdzanowska et al., 1999). Rat hybridoma Abs 187.1 (ATCC
HB58) and G2a-3-40-6.8 are specific for mouse Cκ and CHγ2a.
They were purified from hybridoma culture medium by
adsorption/elution from protein G agarose (Piercenet.com),
concentrated as described above and biotinylated with EZ-
LinkTM NHS-Biotin (Pierce) according to the manufacturer's
protocol. Human C1q (huC1q) was purchased from Sigma and
Calbiochem. Goat-anti-huC1q (gt-α-huC1q), gt-α-huC4 and gt-
α-huC3 were purchased from Calbiochem.
Measurement of Ab-mediated VN activity in vitro
MDCK cells (5 × 104 cells in 0.1 ml ISC-CM 5%FCS) were
seeded the day before assay into 96 well flat bottom plates
(Falcon, Microtest™96). On the day of assay, serial dilutions of
MAb were prepared in flat bottom microtiter plates in 160 μl of
ISC-CM 0.1%BSA (typically eight dilution steps in two repli-
cate columns for generating 12 assay replicates/Ab dilution). An
equal volume of PR8 virus at a concentration of 2000 TCID50/ml
in ISC-CM 0.1%BSA without or with 1% mouse serum was
added to the Ab dilution series. After incubation for 60 min at
37 °C, replicate aliquots (50 μl) of theMAb–virus mixtures were
transferred to MDCK cell monolayers that had been washed
twice with PBS. The plates were incubated for 60 min at 37 °C.
The MAb–virus mixtures were then flicked out and the
monolayers washed twice with PBS. ISC-CM 0.1%BSA
containing trypsin (1 μg/ml) was added to the plates (200 μl/
well) and incubation at 37 °C continued for 3 to 4 days. Culture
supernatants were then tested for presence of virus by HA assay
as described (Scherle et al., 1992). The MAb concentration that
protected 50% of the cultures from infection was determined by
the method of Reed and Munch (1938) and taken as measure of
the MAb's VN activity under the given virus-Ab incubation
condition. Each assay included a titration of the virus dose in the
absence of anti-viral MAb but presence and absence of 0.5%
non-inactivated NMS to confirm that the NMS sample used in
the assay had no VN activity on its own.
Measurement of C1q concentration in serum
PR8 virus immunosorbent plates were prepared as described
(Kavaler et al., 1991). They were blocked with PBSN-1%BSA
and then incubated for 90 min at room temperature with a
saturating dose of MAb H35-C12 (5 μg/ml in PBSN-1%BSA,
25 μl/well). Plates were then incubated sequentially (90 min per
incubation at room temperature, followed by wash) with (1)
dilutions of NMS, or a dilution series of purified huC1q as
standard, (2) goat-anti-huC1q, (3) biotinylated mouse-anti-goat-IgG, (4) ExtrAvidin-AP and (5) pNPP. The plates were read and
analyzed as above. Because goat-anti-huC1q may react more
strongly with huC1q in the standard than with mouse C1q in the
serum samples, the assay provides only a relative measure of
C1q concentration in NMS.
Statistical analyses
Data were analyzed with the statistical software of Prism,
using non-parametric t test for comparison of VNE titers.
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